• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deals search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
Unquote
  • PIPEs

Sofinnova, Ally Bridge lead $108m Mainstay round

  • Katharine Hidalgo
  • Katharine Hidalgo
  • 17 February 2021
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

Sofinnova Partners and Ally Bridge Group have co-led an equity financing of $108m for medical device company Mainstay Medical.

Sofinnova invested through Crossover Fund 1, which closed on €275m in April 2018. The round also saw participation from an undisclosed global medical device company, as well as Sofinnova through its Capital Fund, KCK Group and Fountain Healthcare Partners.

Mainstay intends to use the funds to support the company's commercial launch of ReActiv8 in the US, continued expansion in Europe and Australia, additional post-market clinical studies and research, and general operations.

Mainstay Medical

  • DEAL:

    PIPE

  • VALUE:

    $108m

  • LOCATION:

    Dublin

  • SECTOR:

    Medical equipment

  • FOUNDED:

    2008

Charles Chon, partner and managing director at Ally Bridge Group, and Cédric Moreau, partner at Sofinnova Partners, have also joined the Mainstay Medical board of directors.

Previous funding
In 2010, Soffinova invested $6.2m in Mainstay.

In September 2012, Fountain Healthcare along with Medtronic, Sofinnova, Seventure and Capricorn invested $20m in Mainstay.

In 2014, Mainstay raised €18m in its IPO on Euronext's French and Irish markets. The company issued 851,175 new shares during the offering, priced at €21.15 each, giving it a market cap of €90m. The offer also included an overallotment option for up to 45,953 additional shares. Mainstay's existing backers, which included Sofinnova, Fountain Healthcare, Capricorn, Seventure and two US-based VCs, invested €8m in the offer. David Brabazon, a director at the company, also invested €100,000.

Mainstay raised gross proceeds of €30.1m through the issue of 2,151,332 new ordinary shares to new and existing shareholders in February 2018. The Ireland Strategic Investment Fund (ISIF) participated in the financing, subscribing for 714,285 new shares at a price of €14 apiece, amounting to approximately €10m. Sofinnova, Fountain Healthcare, KCK and several individual investors also participated in the round.

Company
Mainstay manufactures medical devices designed to treat people with chronic low back pain. The company has operations in Ireland, Australia, and the US. The Dublin-based business was founded in 2008.

People
Sofinnova Partners
– Cédric Moreau (partner).
Ally Bridge Group – Charles Chon (partner, managing director).

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • PIPEs
  • UK / Ireland
  • Healthcare
  • Ireland
  • Venture
  • Sofinnova Partners

More on PIPEs

Liad Meidar of Gatemore Capital Management
Gatemore eyes larger stakes in listed SMEs as path to take-privates

With its first closed-end fund in the making, the activist investor will use larger stakes to drive value creation and direct small-cap targets towards PE sales

  • GPs
  • 11 January 2023
Electric cars and fuelling stations
Allego to go public via merger with Apollo-sponsored Spac

Transaction values Allego at a pro forma equity value of USD 3.14bn, including a USD 150m PIPE

  • PIPEs
  • 29 July 2021
Retail delivery services and logistics
Permira makes EUR 1.9bn investment in Adevinta

Deal will see eBay decrease its stake in Adevinta as part of the acquisition of eBay Classifieds

  • PIPEs
  • 14 July 2021
Food production lines and packaging machines
Apollo makes first deal from Impact strategy

Apollo will launch a take-private bid for the recycled cardboard producer on completion of the deal

  • PIPEs
  • 05 July 2021

Latest News

Fund closes in US dollars
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote

  • 05 September 2023
Clinical trials and biotechnology
  • Buyouts
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • 04 September 2023
Public sector software
  • Exits
Partners Group to release IMs for Civica sale in mid-September

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
EMEA Public to Private M&A
  • Investments
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • 04 September 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013